Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | CTSA | P10619 | 9/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 3/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12945561 | 0.79 | LMNA (0.40) | METCTSA | |
| SCHEMBL9258465 | 0.78 | HSD11B1 (0.40) | TRPA1PDK2AKR1C3AKR1C2PTPN5 | |
| SCHEMBL9289342 | 0.75 | GRM5 (0.43) | TRPA1METCTSA | |
| SCHEMBL9261126 | 0.75 | TRPA1 (0.45) | TRPA1PDK2PTPN5 | |
| SCHEMBL27405271 | 0.74 | RXRA (0.42) | METAKR1C3AKR1C2PTPN5TSHR | |
| SCHEMBL9260957 | 0.73 | AKR1C3 (0.55) | PDK2AKR1C3AKR1C2ALDH1A1TSHR | |
| SCHEMBL9260944 | 0.73 | AKR1C3 (0.42) | TRPA1PDK2AKR1C3AKR1C2PTPN5 | |
| SCHEMBL9262993 | 0.73 | TRPA1 (0.43) | TRPA1AKR1C3AKR1C2PTPN5PTPN1 | |
| SCHEMBL24721027 | 0.72 | AKR1C2 (0.41) | AKR1C3AKR1C2PTPN5TSHR | |
| SCHEMBL21652195 | 0.72 | PTGS2 (0.47) | TRPA1PDK2ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | TRPA1 3202/4885MET 2961/4885CTSA 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.